BlackRock Investment Management’s VITAE PHARMACEUTICALS INC COMMON STOCK VTAE Stock Holding History

BlackRock Investment Management’s Portfolio VTAE Stock Details VTAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-101,008	Closed	-$2.11M	–	4032
2016 Q3	$2.11M	Sell	101,008 -177	-0.2%	-$2.04K	﹤0.01%	2114
2016 Q2	$1.09M	Buy	101,185 +54,359	+116%	+$465K	﹤0.01%	2559
2016 Q1	$310K	Buy	46,826 +906	+2%	+$8.24K	﹤0.01%	3070
2015 Q4	$831K	Buy	45,920 +128	+0.3%	+$1.76K	﹤0.01%	2727
2015 Q3	$504K	Sell	45,792 -768	-2%	-$8.16K	﹤0.01%	3021
2015 Q2	$670K	Buy	46,560 +27,211	+141%	+$370K	﹤0.01%	3018
2015 Q1	$227K	Buy	+19,349	New	+$261K	﹤0.01%	3196

BlackRock Investment Management's VTAE Position: Q4 2016 in Review

BlackRock Investment Management sold out of VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) in Q4 2016, closing a stake of 101,008 shares — an estimated $2.11M sold.

BlackRock Investment Management first reported a position in VTAE in Q1 2015 and held it in 7 quarters. The position peaked at $2.11M in Q3 2016. 0 funds tracked by Wall St. Rank hold VTAE as of Q4 2016.

BlackRock Investment Management reported no remaining VITAE PHARMACEUTICALS INC COMMON STOCK position as of Q4 2016 after selling out during the quarter.
BlackRock Investment Management sold 101,008 VITAE PHARMACEUTICALS INC COMMON STOCK shares in Q4 2016, an estimated $2.11M.
BlackRock Investment Management first reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK in Q1 2015 and held it in 7 quarters.
BlackRock Investment Management's VITAE PHARMACEUTICALS INC COMMON STOCK position peaked at $2.11M in Q3 2016.
0 funds tracked by Wall St. Rank held VITAE PHARMACEUTICALS INC COMMON STOCK as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.